Clinical Trial Detail

NCT ID NCT03242915
Title Pembrolizumab in Combination With Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Targetable Genetic Alterations, Previously Treated With Appropriate Targeted Agents, With Progressive Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Rogel Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Age Groups: adult senior

No variant requirements are available.